---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-006546"
form_type: "8-K"
ticker: "CRVO"
cik: "0001053691"
company_name: "CervoMed Inc."
filed_at: "2024-03-05T23:59:59+00:00"
generated_at: "2026-06-05T03:20:23.505185+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# CervoMed reports Phase 2a biomarker data: neflamapimod reduces GFAP, correlates with clinical outcomes in DLB

## Summary
- In pure DLB patients, neflamapimod reduced GFAP by mean 10.6 pg/mL vs 14.1 increase with placebo (p=0.04).
- GFAP reduction correlated with improvement on CDR-SB (r=0.542, p=0.036) in neflamapimod-treated pure DLB patients.
- Preclinical data from UCL shows neflamapimod enhances axonal transport in tauopathy mouse model of FTD.
- CEO states data support clinical efficacy in DLB and rationale for evaluating neflamapimod in frontotemporal dementia.

## SEC filing metadata
- accession: 0001437749-24-006546
- form_type: 8-K
- ticker: CRVO
- cik: 0001053691
- company_name: CervoMed Inc.
- filed_at: 2024-03-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1053691/000143774924006546/0001437749-24-006546-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1053691/000143774924006546/crvo20240304_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-006546
- JSON: https://secwatch.observer/filing/0001437749-24-006546.json
- Plain text: https://secwatch.observer/filing/0001437749-24-006546.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.